Verteporfin launched into Japanese market

New York-Japanese patients have access to the only treatment for some forms of wet age-related macular degeneration (AMD) with the launch of verteporfin (Visudyne, QLT PhotoTherapeutics/Novartis Ophthalmics) in Japan.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.